Phase
Condition
Obesity
Aging
Diabetes Prevention
Treatment
Healthy Lifestyle
Lifestyle therapy
Metformin Hydrochloride
Clinical Study ID
Ages 65-85 All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
BMI = or > 30 kg/m2
Stable body weight (plus/minus 2 kg) during the past 6 months
Sedentary (regular exercise <1 h/wk or <2 x/wk for the last 6 months)
Willing to provide informed consent
Exclusion
Exclusion Criteria:
Any major chronic diseases, or any condition that would interfere with exercise ordietary restriction, or use of metformin, in which exercise, dietary restrictions,or metformin are contraindicated, or that would interfere with interpretation ofresults
Cardiopulmonary disease (e.g. recent MI, unstable angina, stroke) or unstabledisease (e.g., NYHA Class III or IV congestive heart failure, severe pulmonarydisease requiring steroid pills or the use of supplemental oxygen) that wouldcontraindicate exercise or dietary restriction
Severe orthopedic (e.g. awaiting joint replacement) and/or neuromuscular (e.g.multiple sclerosis, active rheumatoid arthritis) disease or impairments that wouldcontraindicate participation in exercise
Renal impairment as defined by an estimated glomerular filtration rate (eGFR of lessthan 30 mL/min/1.73 m2) in which metformin is contraindicated
Other significant co-morbid disease that would impair ability to participate in theexercise intervention (e.g. severe psychiatric disorder [e.g. bipolar,schizophrenia], excess alcohol use [>14 drinks per week])
Severe visual or hearing impairments that would interfere with following directions
Significant cognitive impairment, defined as a known diagnosis of dementia orpositive screening test for dementia using the Mini-Mental State Exam (i.e. MMSEscore <24)69
Uncontrolled hypertension (BP>160/90 mm Hg)
History of malignancy during the past 5 years (except non-melanoma skin cancers)
Current use of bone acting drugs (e.g. use of estrogen, or androgen containingcompound,raloxifene, calcitonin, parathyroid hormone during the past year orbisphosphonates during the last two years)
Osteoporosis (T-score -2.5 and below on hip or spine scan) or history of fragilityfractures
Known history of diabetes mellitus or any of the following:
fasting blood glucose of 126 mg/dl, 2-h blood glucose 200 mg/dl in the OGTT, orHbA1c of 6.5% or >
Terminal illness with life expectancy less than 12 months, as determined by aphysician
Use of any drugs or natural products designed to induce weight loss within pastthree months
History of excessive alcohol consumption (e.g. 8 or more drinks a week for women and 15 or more drinks a week for men)
Positive exercise stress test for ischemia or any indication for early terminationof exercise stress testing
Taking metformin or any other glucose lowering drug
Lives outside of the study site or is planning to move out of the area in the next 2years
Study Design
Study Description
Connect with a study center
Michael E. DeBakey VA Medical Center, Houston, TX
Houston, Texas 77030-4211
United StatesSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.